Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUTH: Raloxifene Use for The Heart
NCT00190593Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary heart disease (CHD) and Invasive breast cancer (IBC) comparing Raloxifene with Placebo (2 arms). Primary endpoints: Time to first occurrence of coronary death, non-fatal myocardial infarction, or hospitalized acute coronary syndrome and Time to first occurrence of invasive breast cancer. Started Jun 1998; status: completed.
02
Drugs
raloxifene
03
Conditions
coronary heart disease (CHD)Invasive breast cancer (IBC)
Beyond the preview
Go deeper on NCT00190593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190593.